OMA Toronto Sheraton Centre Hotel 4 hour course by GLENN TECKER of TECKER INT.LLC.

www.tecker.com Approx 300 OMA members recorded opinions on responsibilities of OMA Board; Council; CEO; Assemblies - Diagnostic, Medical,Primary practice, Surgical; Sections; Districts and Branch societies. Electronic voting was by table, not individual. ONTARIO 2013 (Stats Can.) Primary physicians: 12,933 Specialists: 10,475

TORONTO: North York (community) hospital anaesthetist guilty of 21 sexual acts..

CBC News A Toronto court has found Indo-Scot Anaesthetist Dr.George Doodnaught, MBChB (Glasgow 1974)FRCPC(anaes.1981), guilty of sexually assaulting 21 women while they were under conscious sedation in a hospital.

ONTARIO HEALTH INNOVATION COUNCIL -14 members

ontario.ca/innovation-news 9-male;5-female. Technical experts include: Pres & CEO MaRS INNOVATION Dr. R.HOFSTEIN BSc(Phys/Chem. Hebrew Univ.) MSc & PhD(Chem.Weizmann Instit.) Pres.,MEDTRONIC(Can.)N.FRASER.B.Applied Sc.(Chem engineering U.B.C.)P.Eng., MBA(Ivey) Pres & CEO Boehringer Ingelheim(Can.)Prof.Dr.T.WITEK MPH(Yale) Doctor Public Health(Columbia) MBA (Henley,UK)

OMA ad in TORONTO STAR: $34,000

Whole page ad in Toronto star Nov 16 p. A 18 at $34,000 "Ontario's doctors are making health care better. Doctors diagnose,treat,and cure. They're leaders in prevention. But it's their unique understanding of health care that helps them transform the system so that you and your family get the exceptional care you need. Find out how they're doing it at OntariosDoctors.com OMA Ontario Medical Association"

LANCET: Antibiotic resistance

http://www.reactgroup.org/uploads/news/Comments-on-The-Lancet-Infectious-Diseases-Commission-on-Antibiotic-Resistance-Nov2013.pdf COMMENT: OMA could force CPSO to reject time-wasting, expensive complaints against MDs for NOT prescribing antibiotics on demand by patients.

ProMED: FREE ebook from GIDEON on Infectious diseases of the Philippines.

A ProMED-mail post ProMED-mail is a program of the International Society for Infectious Diseases Date: Sat 16 Nov 2013 From: Uri Blackman [edited] A massive effort is underway to supply medical assistance to the Philippines. ProMED has arranged to supply a free copy of Infectious Diseases of the Philippines, 2013, to all subscribers. This e-book (411 pages, 88 graphs, 1869 references) is the only comprehensive source for background information on the status of every individual infectious disease in the Philippines. To obtain Infectious Diseases of the Philippines, 2013: 1. click on the following link: 2. click on "add to cart" 3. click on "add a coupon" and enter ProMED 4. click on "update" 5. fill in identification and mailing information where indicated You will receive a link for the e-book by e-mail, which you can open on your computer or mobile device. Infectious Diseases of the Philippines, 2013, is one in a series of 419 e-books (105 000 pages), with one title dedicated to every disease and every country in the world. All books are updated yearly. The publisher has agreed to offer a 50 percent discount on all titles to ProMED subscribers. To obtain any of these books at a discount: 1. click on the desired title(s) listed at and 2. follow instructions as for Infectious Diseases of the Philippines, 2013 3. at the stage of "add a coupon" enter 50promed13 -- Uri Blackman [We expect that the conditions in the typhoon-affected areas of the Philippines may well result in emerging disease outbreaks and increases in endemic diseases. ProMED appreciates this offer from our friends at GIDEON. - Mod.LM]

CANADA : PROVINCIAL MEDICINE VARIES.

COMMENT: For non-Canadian readers, the practice of Canadian medicine varies according to Provincial political decisions. Private Hospitals legally exist in QUEBEC. Payment for expensive medication varies according to Provincial political policy. QUEBEC and ALBERTA are the most generous, (allowing MDs to make independent clinical decisions). Ont.Med Review Nov. 2013. The Ont.Govt has reduced all fees by 0.5% about $1000 a year for a GP. New political controls for Optical Coherent Tomography, colonoscopy and cervical cancer screening. Patients can get "private medicine" ,which is officially not permitted by the Canada Health Act (except in Quebec), by subscribing about $3000/year to "Wellness Clinics" which use a legal device providing non-Gov.-paid advice from Dietitians, Physiotherapists et al. Examples in Toronto are Cleveland clinic Canada, MedCan, MediSys, together with GPs with Executive clients. MDs are not permitted to practice in Provinces where they are not licenced. Lawyers can practice in another Province for 100 days a year. An Ontario MD in Ottawa cannot practice across the river in Hull,Quebec.

Toronto Univ..SUNNYBROOK HOSP. :Paroxysmal Nocturnal Haematuria.

Paid by OHIP: approx $250,000 a year. Soliris® (eculizumab), is a first-in-class terminal complement inhibitor discovered, developed and commercialized by ALEXION pharmaceuticals,Inc.. Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH)1, a progressive and life-threatening disease characterized by the excessive destruction of red blood cells (hemolysis).1,2,3 Soliris is the first and only therapy approved for the treatment of PNH to reduce hemolysis. In the United States and European Union, Soliris is also approved for the treatment of patients with atypical hemolytic uremic syndrome (aHUS), an ultra-rare, life-threatening, genetic disease that can progressively damage vital organs, leading to stroke, heart attack, kidney failure and death.4,5 Soliris is the first and only therapy approved for the treatment of aHUS. Specifically, Soliris is indicated for the treatment of patients with aHUS to inhibit complement-mediated thrombotic microangiopathy, or TMA. The effectiveness of Soliris in aHUS is based on the effects on TMA and renal function. Prospective clinical trials in additional patients are ongoing to confirm the benefit of Soliris in patients with aHUS. Soliris is not indicated for the treatment of patients with Shiga toxin E coli-related hemolytic uremic syndrome (STEC-HUS). Soliris works by selectively targeting and blocking the complement cascade—a normal part of the immune system that, when activated inappropriately, plays a role in serious diseases like PNH and aHUS. Soliris has earned some of the pharmaceutical industry’s highest honors for innovation, including the 2008 Prix Galien USA Award for Best Biotechnology Product with broad implications for future biomedical research and the 2009 Prix Galien France Award in the category of Drugs for Rare Diseases. To learn more about Soliris, visit www.Soliris.net. Sunnybrook Haematology Dept: Prof. Richard A.WELLS MD(Newfoundland 1985) D.Phil(Oxon) FRCPC (Int.Med & Haematology).